Primary invasive carcinoma of the vagina

Manetta, Alberto; Gutrecht, EL; Ml, Berman; Disaia, P

doi:10.1016/0020-7292(91)90337-5

Cited by 10 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of all patients in this series with LDRB produced a crude 5‐year survival rate of 41%, while the actuarial 3 year overall survival with HDRB was 51% and 3‐year disease‐specific survival was 66%. Our results from treating vaginal cancer with LDRB are consistent with the findings by other authors who published their experience over the past 10 years (6, 8, 11–17). The Annual Report (18), which includes more than 6000 cases of carcinoma of the vagina, reported a crude 5‐year survival of 38.6% for the period from 1979–81 and an actuarial 5‐year survival rate of 46.8% for the period of 1987–89.…”

Section: Discussionsupporting

confidence: 92%

Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy

Kucera¹,

Mock²,

Knocke³

et al. 2001

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy

Kucera¹,

Mock²,

Knocke³

et al. 2001

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…The most common symptom in PCV is vaginal bleeding and/or discharge, especially in more ad-vanced stages and indeed 38 (60%) of our patients did consult their doctor because of vaginal bleeding, a figure which corresponds well with previous findings (2,4,5) . Vaginal discharge, alone or in combination with other symptoms, was also a common initial symptom.…”

Section: Discussionsupporting

confidence: 91%

“…previous studies have been small and treatment was often heterogeneous and thus difficult to evaluate. Possible risk factors for PCV include poor socioeconomic status, genital human papilloma virus (HPV) infections, vaginal pessaries, a history of an abnormal Pap smear or early hysterectomy (1,2,4,5,13,25,26) . Primary carcinoma of the vagina usually occurs in the older age groups in postmenopausal women, with only a minority of patients being younger than 50 years of age.…”

mentioning

confidence: 99%

Primary invasive cancer of the vagina

Malmström¹,

Engquist²

1997

Int J Gynecol Cancer

View full text Add to dashboard Cite

The study comprised 63 patients with primary carcinoma of the vagina (PCV) treated between 1964 and 1994 and retrospectively analyses the survival rates and time in relation to various prognostic factors. The overall median age at diagnosis was 64 (range 27–94) years. Forty‐one (65%) of the cases were squamous cell carcinomas. The number of patients in various stages were: I/6 (9%), II/34 (54%), III/13 (21%) and IV/10 (16%), and according to histologic dedifferentiation: high grade 23 (37%), medium grade 17 (27%), and low grade 12 (19%); not recorded, 11 (18%). In 12 patients the primary treatment was surgical and five of these patients were operated on a second time at a later occasion (two vaginectomies and 10 vaginal resections); surgical treatment after previous radiotherapy or chemotherapy was given to another 12 patients (four vaginectomies and eight vaginal resections). In summary, 24 (38%) patients were given surgical treatment alone or in combination with other treatment modalities. Fifty‐five (87%) patients were treated alone or in combination with other treatment modalities. Fifty‐five (87%) patients were treated with external irradiation with a median dose of 40 (range, 21–76) Gray. Fifty (79%) patients were administered brachytherapy with a median dose of 2880 (range, 400–4900) mgRaH. In only eight (13%) patients no radiotherapy was given. Chemotherapy was given to 10 (16%) patients, three of these also received second‐line chemotherapy. Chemotherapy after surgical or irradiation therapy was given to six (9%) patients. The 5‐year corrected survival rate (5YSR) and median survival time (MST) were 52%/93 months for stage I patients, 50%/30 months for stage II, 24%/10 months for stage III, and 20%/11 months for stage IV. The 5YSR/MST in high grade tumors was 32%/8, in medium grade 36%/13, and in low grade tumors 43%/15 months. The median recurrence‐free interval was 18 months (range, 6–94). A trend for better survival was found in patients without a history of serious illness and in a subgroup of patients who were not administered chemotherapy. The most important prognostic factors in this study were tumor stage (P = 0.02), patient age (P = 0.002) and our Prognostic Index (P = 0.01). No differences in survival were found analyzing other patient or tumor characteristics. Of all the patients studied, 14 (22%) are living without evidence of cancer, 10 (16%) have died due to intercurrent disease and 39 (62%) have died of PCV.

show abstract

“…In some centers, especially a few decades ago, this carcinoma was treated by radiotherapy only (6). Today the percentage of patients receiving radiotherapy ranges between 53% and 94% (7,19). We used radiotherapy alone or in combination with other treatments in 81% of the cases.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic and prognostic considerations in primary carcinoma of the vagina

Leminen

Forss

Lehtovirta

1995

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

We analyzed 46 patients with primary carcinoma of the vagina treated between 1969 and 1990. Median age of the patients was 67 years (range 33-89 years). Most (52%) of them were obese and 35% were nulliparous. Four (9%) had suffered from other gynecologic carcinoma and had been operated six to 23 years before the current carcinoma. Forty (87%) patients had squamous cell carcinoma. Stage 0 (carcinoma in situ) was found in three (7%) cases and stage I-IV in 21 (54%), 10 (22%), four (9%) and eight (17%) cases, respectively. Most (81%) of the patients were treated with radiotherapy (alone or in combination with other treatments): combination of brachytherapy and external radiotherapy were used in 45% of the cases. Surgery was used in all stage 0 cases and in 52% of stage I cases. Recurrence of the disease was found in 20 (43%) cases during the follow-up of 10 years. Most often (40%) site of the recurrence was the vagina. Both 5- and 10-year survival were 38%. Stage and extent of the tumor were independent prognostic factors in stepwise multivariate analysis.

show abstract

Primary invasive carcinoma of the vagina

Cited by 10 publications

References 33 publications

Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy

Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy

Primary invasive cancer of the vagina

Therapeutic and prognostic considerations in primary carcinoma of the vagina

Contact Info

Product

Resources

About